EBCOG Part 1 Random Practice Ques Paper F(E.M.Q)

A. Stage 1A
B. Stage 1B
C. Stage 2
D. Stage 3A 1
E. Stage 3A 2
F. Stage 3B 1
G. Stage 3B 2
H. Stage 3C
I. Stage 4A 1
J. Stage 4A 2
K. Stage 4B

1. Squamous carcinoma of the vulva, which is 1cm in diameter with a solitary nodal mass in the left internal iliac region suggesting metastasis.

2. A single 1.8 cm midline vulval lesion at the forchette with 0.9 mm stromal invasion. There are no palpable lymph nodes.

3. A 4 cm midline vulval tumour invading 3mm into the lower urethra.

4. A 4 cm midline vulval tumour invading 3mm into underlying stroma only.

5.A 2.5 cm right vulval mass with one left inguino-femoral node metastasis of 5mm diameter.

6. A 2.5 cm tight vulval mass with two left inguino-femoral node metastasis of 5mm diameter.

A.Alendronic acid
B. Insertion of LNG-IUS
C. Local vaginal oestrogen therapy
D. Medroxy progesterone acetate
E. Oral combined cyclical HRT
F. Oral phytoestrogens
G. Raloxifen
H. SSRI antidepressants
I. Sildenafil citrate
J. Testosterone supplementation with systemic HRT
K. Tibolone
L. Transdermal oestrogen-only HRT

7.A 57-yr old woman suffering from severe menopausal vasomotor and lower genital tract symptoms; last period 12 months ago and known large uterine fibroids.

8. A 56-yr old woman with a history of breast cancer, on aromatase inhibitors, with a 6 months history of distressing night sweats.

9. A 58-yr old woman who has had a hysterectomy with diagnosed hypoactive sexual desire disorder (HSDD).

10.A 65-yr old nulliparous woman (normal BMI) with a history of breast cancer, now presenting with osteoporosis.

11. A 30-yr old nulliparous woman has been diagnosed with severe endometriosis. She has been commenced on long-term LHRH-A treatment.

12. A 42-yr old multiparous woman with a history of cervical carcinoma, treated with surgery and radiotherapy. She is now complaining of dyspareunia.

A. Clinical audit
B. Clinical effectiveness
C. Clinical governance
D. Education and training
E. Justice
F. Openness
G. Patient and public involvement
H. Research and development
I. Risk management
J. Staffing and staff management
K. Using information and IT

13. A measure of the extent to which a particular intervention works.

14. Processes which are open to public scrutiny, while respecting individual patient and practitioner confidentiality and which can be justified openly.

15. A framework through which NHS organization are accountable for continually improving the quality of their services and safeguarding high standards of care by creating an environment in which excellence in clinical care will flourish.

16. The review of clinical performance, the refining of clinical practice as a result and the measurement of performance against agreed standards – a cyclical process of improving the quality of clinical care.

17. The identification, assessment, and prioritization of risks, followed by coordinated and economical application and resources to minimize, monitor and control the probability and/or impact of unfortunate events.

A. Amitriptyline
B. Anterior colporrhaphy
C. Artificial urinary sphincter
D. Augmentation cystoplasty
E. Botulinum A toxin
F. Cimetidine
G. Colposuspension (Bursh)
H. Intraurethral NASHA/DX copolymer injection
I. Needle suspension
J. Rectus fascia pubovaginal sling
K. Sacral neuromodulation
L. TOT
M. TVT
N. Urinary diversion

18. An 83-yr old woman in poor medical health with urodynamic stress incontinence and normal voiding parameters.

19. A 44-yr old woman with urge incontinence and severe detrusor overactivity on urodynamic assessment. This is unresponsive to conservative therapy and anticholinergic medication.

20. A 56-yr old woman with urodynamic stress incontinence and no previous surgery; her family is complete and there is no prolapse on examination.